Ablative Solutions added to its coffers yesterday, reporting a $2.7 million raise out of a hoped-for $5 million as it works to develop its perivascular renal denervation technology for treating high blood pressure.
Menlo Park, Calif.-based Ablative said 41 unnamed investors joined the debt, options and warrants round.
The company reported raising $1.1 million last April.
Unlike other renal denervation technologies, which use radiofrequency energy to deaden the nerves lining the renal arteries, delivered through the artery walls, the Ablative Solutions approach delivers the energy directly to the nerves themselves, according to its website.
Founded in 2011, Ablative Solutions raised a $5.3 million Series A round last year.